LEGNLegend Biotech Corporation
Price
-45%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 27% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for LEGN today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Mixed
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
We are a global biopharmaceutical company engaged in the discovery, development, manufacturing and commercialization of novel cell therapies for oncology and other indications. Our team of approximately 2,900 employees in the United States, China and Europe, our differentiated technology, global development and manufacturing strategy and expertise provide us with the ability to generate, test and manufacture next-generation cell therapies targeting indications with high unmet needs.
In the company’s own words · 20-F filed Mar 10, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
For the full year FY2025, revenue was $1.03B (+64% year on year) and net income −$297M.